Brainstorm Cell Therapeutics Management
Management criteria checks 4/4
Brainstorm Cell Therapeutics' CEO is Chaim Lebovits, appointed in Sep 2015, has a tenure of 9.67 years. total yearly compensation is $750.30K, comprised of 51.6% salary and 48.4% bonuses, including company stock and options. directly owns 2.54% of the company’s shares, worth $213.02K. The average tenure of the management team and the board of directors is 3.3 years and 5.2 years respectively.
Key information
Chaim Lebovits
Chief executive officer
US$750.3k
Total compensation
| CEO salary percentage | 51.65% |
| CEO tenure | 9.7yrs |
| CEO ownership | 2.5% |
| Management average tenure | 3.3yrs |
| Board average tenure | 5.2yrs |
Recent management updates
Recent updates
Brainstorm Cell Therapeutics: Upcoming BLA In ALS
Aug 21BrainStorm Cell Therapeutics Q2 2022 Earnings Preview
Aug 12Is Brainstorm Cell Therapeutics (NASDAQ:BCLI) In A Good Position To Invest In Growth?
Aug 05
Is Brainstorm Cell Therapeutics (NASDAQ:BCLI) In A Good Position To Invest In Growth?
Mar 22Is Brainstorm Cell Therapeutics (NASDAQ:BCLI) In A Good Position To Invest In Growth?
Nov 26Is Brainstorm Cell Therapeutics (NASDAQ:BCLI) In A Good Position To Deliver On Growth Plans?
May 02Who Has Been Buying Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) Shares?
Feb 21
Here's Why We're Watching Brainstorm Cell Therapeutics' (NASDAQ:BCLI) Cash Burn Situation
Jan 17What Percentage Of Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) Shares Do Insiders Own?
Dec 13CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Mar 31 2025 | n/a | n/a | -US$11m |
| Dec 31 2024 | US$750k | US$388k | -US$12m |
| Sep 30 2024 | n/a | n/a | -US$14m |
| Jun 30 2024 | n/a | n/a | -US$13m |
| Mar 31 2024 | n/a | n/a | -US$16m |
| Dec 31 2023 | US$1m | US$442k | -US$17m |
| Sep 30 2023 | n/a | n/a | -US$17m |
| Jun 30 2023 | n/a | n/a | -US$22m |
| Mar 31 2023 | n/a | n/a | -US$24m |
| Dec 31 2022 | US$1m | US$500k | -US$24m |
| Sep 30 2022 | n/a | n/a | -US$25m |
| Jun 30 2022 | n/a | n/a | -US$24m |
| Mar 31 2022 | n/a | n/a | -US$23m |
| Dec 31 2021 | US$1m | US$500k | -US$24m |
| Sep 30 2021 | n/a | n/a | -US$30m |
| Jun 30 2021 | n/a | n/a | -US$29m |
| Mar 31 2021 | n/a | n/a | -US$30m |
| Dec 31 2020 | US$2m | US$500k | -US$32m |
| Sep 30 2020 | n/a | n/a | -US$28m |
| Jun 30 2020 | n/a | n/a | -US$29m |
| Mar 31 2020 | n/a | n/a | -US$26m |
| Dec 31 2019 | US$1m | US$500k | -US$23m |
| Sep 30 2019 | n/a | n/a | -US$21m |
| Jun 30 2019 | n/a | n/a | -US$18m |
| Mar 31 2019 | n/a | n/a | -US$17m |
| Dec 31 2018 | US$2m | US$500k | -US$14m |
Compensation vs Market: Chaim's total compensation ($USD750.30K) is about average for companies of similar size in the US market ($USD644.97K).
Compensation vs Earnings: Chaim's compensation has been consistent with company performance over the past year.
CEO
Chaim Lebovits (53 yo)
Mr. Chaim Lebovits is Chief Executive Officer of Brainstorm Cell Therapeutics Inc. from September 22, 2015 and is its President January 2023. Mr. Lebovits joined the Brainstorm Cell Therapeutics Inc. on Ju...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President & CEO | 9.7yrs | US$750.30k | 2.54% $ 213.0k | |
| Executive VP & Chief Medical Officer | 1.8yrs | US$498.58k | 1.01% $ 84.3k | |
| Executive VP | 8.2yrs | US$266.14k | 0.74% $ 62.0k | |
| Interim CFO & Controller | 12.4yrs | US$146.78k | 0.56% $ 47.0k | |
| Executive VP & COO | less than a year | no data | 0.66% $ 55.1k | |
| Chief Scientific Advisor | no data | no data | no data | |
| Senior Vice President of Patient Advocacy & Government Affairs | 3.3yrs | no data | no data | |
| Senior Vice President of Research and Development | 1.3yrs | no data | no data |
Experienced Management: BCLI's management team is considered experienced (3.3 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Executive VP | 10.9yrs | US$266.14k | 0.74% $ 62.0k | |
| Independent Chairman of the Board | 5.2yrs | no data | 0.30% $ 25.2k | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Co-Founder & Independent Vice Chair of the Board | 21yrs | no data | 0.33% $ 27.3k | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Independent Director | 3.6yrs | US$60.00k | 0.15% $ 12.7k | |
| Chairman of Scientific Advisory Board | 7.2yrs | no data | no data | |
| Independent Director | 7.3yrs | US$12.50k | 0.17% $ 14.6k | |
| Member of Scientific Advisory Board | 2.3yrs | US$4.46m | no data | |
| Director | 1yr | US$572.70k | 0.43% $ 36.2k | |
| Independent Director | 1.9yrs | no data | 0.20% $ 17.1k |
Experienced Board: BCLI's board of directors are considered experienced (5.2 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/29 22:37 |
| End of Day Share Price | 2025/05/29 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Brainstorm Cell Therapeutics Inc. is covered by 4 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| null null | ACF Equity Research Limited |
| Jason Kolbert | H.C. Wainwright & Co. |
| Jason McCarthy | Maxim Group |